Compass Therapeutics (NASDAQ: CMPX) net income
Compass Therapeutics reported a net loss of $66.5m for fiscal 2025; in fiscal 2024 it reported a net loss of $49.4m. Earnings per share were −$0.42.
Compass Therapeutics's best year of the last 7 was fiscal 2020. It reported a loss in 7 of those 7 years.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Net income by fiscal year
| Fiscal year | Net income | Change | Net margin | Earnings per share |
|---|---|---|---|---|
| 2025 | −$66.5m | — | — | −$0.42 |
| 2024 | −$49.4m | — | −5,808.8% | −$0.36 |
| 2023 | −$42.5m | — | — | −$0.33 |
| 2022 | −$39.2m | — | — | −$0.37 |
| 2021 | −$82.2m | — | — | −$1.31 |
| 2020 | −$29.5m | — | — | — |
| 2019 | −$34.7m | — | — | — |
The change compares each fiscal year with the one before and is not calculated when the previous year closed with a loss. Net margin is net income over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Compass Therapeutics net income compared with its sector
By net income for its latest fiscal year, Compass Therapeutics ranks 287th of the 501 US health care companies with a page on Celsmar.
| Rank | Company | Net income | Net margin |
|---|---|---|---|
| 285th | Arcturus Therapeutics | −$65.8m | −80.2% |
| 286th | Tarsus Pharmaceuticals | −$66.4m | −14.7% |
| 287th | Compass Therapeutics | −$66.5m | — |
| 288th | Cytek Biosciences | −$66.5m | −33.0% |
| 289th | Ocugen | −$67.8m | −1,537.4% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the net income of Compass Therapeutics
- How much did Compass Therapeutics earn in fiscal 2025?
- Compass Therapeutics reported a net loss of $66.5m for fiscal 2025. In fiscal 2024 it reported a net loss of $49.4m.
- What are the earnings per share of Compass Therapeutics?
- They were −$0.42 in fiscal 2025, compared with −$0.36 in fiscal 2024.
- Where does Compass Therapeutics rank in its sector by net income?
- It ranks 287th of the 501 US health care companies with a page on Celsmar, by net income for its latest fiscal year.
- Where do the figures for Compass Therapeutics come from?
- From the annual report (Form 10-K) that Compass Therapeutics files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Compass Therapeutics files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019. More on Compass Therapeutics: the Compass Therapeutics page · annual accounts · revenue · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.